Primary outcome
Anxiety, anxiety, Suicidality, Suicidal Ideation, depression, Depression
DISORDER, SECONDARY, POSITIVE
At 3 months participants in the intervention arm reported greater reductions in depression on the HADS (mean difference 1.2 (95% CI 0.4 to 1.9), p=0.003), with a moderate effect size (0.5 (95% CI 0.2 to 0.9)). There was no between-group difference on anxiety on the HADS (Summary statistics and results from mixed model analysis of primary and secondary outcomesEffect size was calculated by the difference in least square means between intervention and EUC from mixed model divided by the pooled SD.Sleep Impairment Index (total score range: 0–20; higher scores indicate more severe sleep impairment).COVID Concerns Scale, COVID-19 Stress Scale (each scale total score range: 0–24; higher scores indicate more severe stress); EUC, enhanced usual care; GAD-7, Generalised Anxiety Disorder Scale (total score range: 0–21; higher scores indicate more severe worry); HADS, Hospital Anxiety and Depression Scale (depression subscale score range: 0–21; anxiety subscale score range: 0–21; higher scores indicate elevated anxiety or depression); LS, least square; PANAS, Positive and Negative Affect Schedule (subscale total score range: 10–50 on positive and negative scales, respectively; higher scores indicate more greater positive and negative mood, respectively); Quality of life, Australian Quality of Life Scale (total score range: 20–100; higher scores indicate poorer quality of life); Suicidality, Suicidal Ideation Attributes Scale (total score range: 0–50; higher scores indicate more severe suicidality).